[Skip to the notes](#main) [**Sermorelin** Care notebook](/) When sermorelin starts the search Caution notes # Know when to pause. A few claims call for a pause. Start with the product, the prescription and who will answer your questions. In this note [Approval claims](#claims) [The prescription](#prescription) [Research labels](#research-label) [Reported effects](#effects) [Evidence gaps](#unknowns) [Urgent help](#help) [Report a concern](#report) ## Pause at an approval claim A compounded medicine is one that a pharmacist or doctor prepares for an order. As of September 26, 2026, a compounded medicine is not approved by the FDA, the US medicine agency. “FDA registered” means a business is listed with the agency; as of September 26, 2026, that listing is not approval of the business or its medicines. Ask which exact medicine it says has FDA approval, and ask for a link to that medicine’s FDA approval entry. Open the link and compare the medicine’s name. For a doctor or pharmacy licence, use the state lookups in the notes on finding care. [Check a doctor or pharmacy licence](/open-notebook/#check-a-name) [Read the FDA explanation of approval](https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved) ## Pause if there is no real prescription As of September 26, 2026, federal law prohibits dispensing prescription medicine unless there is a valid prescription. Medical board advice rejects writing a prescription from a questionnaire alone if it misses important health details or gives the doctor no way to ask more questions. A questionnaire can be part of care if the doctor can learn enough about you and ask more questions; the state’s prescribing rules still apply. Ask who reviews your answers and how they can question you about gaps or unclear details. Find out how to ask that reviewer questions of your own. [Read the medical boards’ care guidance](https://www.fsmb.org/siteassets/advocacy/policies/fsmb-workgroup-on-telemedicineapril-2022-final.pdf) ## A research label is not a care plan FDA warning letters in March and August 2026 challenged sellers who called products “for research use only” while promoting them for people to inject. Those words on the package did not change how the sellers were offering the products. Those letters stated the FDA’s concerns about particular businesses; they were not final court decisions about every product. Keep the search focused on an assessment and a named, licensed pharmacy. A research product page does not answer those care questions. ## What the older studies reported Evidence note ### Brief face redness and soreness where the needle went in Older sermorelin studies most often reported a briefly reddened face and soreness at the spot where the injection was given. What else to know Those reports came largely from studies in children in the 1990s, not from current compounded products used by adults. [Read the published review summary](https://pubmed.ncbi.nlm.nih.gov/18031173/) ## Ask about the gaps, too As of September 28, 2026, sermorelin has no current FDA-checked medicine information for doctors explaining how often side effects happen or its use in pregnancy. That official information is a document for doctors, separate from the pharmacy’s directions on a bottle. Before a treatment decision, mention pregnancy plans, health conditions, medicines and supplements. Ask the doctor what is known, what is uncertain and what would change the plan. Evidence note ### Concerns about raising the body’s hormone levels The body makes growth hormone as a chemical messenger. FDA reviews from 2024 discussed ipamorelin and CJC-1295, two other substances that make the body release more growth hormone. They described possible rises in blood sugar, fluid build-up and tumour risk when growth hormone levels rise. Those concerns came from official warnings for doctors who prescribe growth hormone medicines; they were not an FDA finding about sermorelin in adults. [Read the FDA review of related drugs](https://www.fda.gov/media/182088/download) ## Know when to get urgent help Severe trouble breathing, difficulty swallowing, or swelling of your face or tongue may signal a severe allergic reaction. MedlinePlus directs people with severe allergic-reaction symptoms to call 911 or the local emergency number. [Read the MedlinePlus emergency guidance](https://medlineplus.gov/ency/article/000844.htm) ## Report a suspected medicine problem You can report a suspected medicine problem to the FDA through MedWatch, its free reporting programme for patients as well as health workers. Submitting a report puts a concern on record without establishing that the medicine caused it. [Open the FDA MedWatch information](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) [Return to the checks **Check the names behind the offer**](/open-notebook/#check-a-name) This notebook helps you ask about sermorelin care; it is a guide, never a clinic or a seller. [Read as text](/caution-notes/index.md) [Start again](/) [Start](/) [Find](/open-notebook/) [Ask](/question-notes/) [Cost](/budget-notes/) [Read](/source-notebook/) [Pause](/caution-notes/)